Hepatology On The Nile 4

Cairo Marriott Hotel

5-6 October, 2016

Expected impact of HCV treatment and SVR: Is HCC incidence increasing?

Massimo Colombo

University of Milano, Milan, Italy

 

 

 

 

Update on current result of DAAs IN HCV

Geoffrey Dusheiko

University College London School of Medicine and Royal Free Hospital, London, UK

 

 

 

 

 

 

HCV genotype 4: update

Tarik Asselah

Hôpital Beaujon, Clichy –France

 

 

 

 

 

 

Treatment of Hepatitis C in special populations

Massimo Colombo

University of Milano, Milan, Italy

 

 

 

 

 

Hepatitis B in 2016 and beyond

Geoffrey Dusheiko

University College London School of Medicine and Royal Free Hospital, London, UK

 

 

 

 

 

HBV cure: Therapeutic perspectives

Tarik Asselah

Hôpital Beaujon, Clichy –France

 

 

 

 

 

 

Challenges in HBV

Panel Discussion

Panelists: Imam Waked, Geoffrey Dusheiko, Tarik Asselah,

 

 

 

 

 

 

Diagnosis of benign liver tumours: Is imaging enough?

Valerie Vilgrain

Hôpital Beaujon, Clichy –France

 

 

 

 

 

 

Whom, how and when to start/stop screening?

Peter Galle

Universitätsmedizin, Germany

 

 

 

 

 

 

Current and future burden of HCC in Egypt

Imam Waked

National Liver Institute, Egypt

 

 

 

 

 

Staging systems in HCC & BCLC debate

Peter Galle

Universitätsmedizin, Germany

 

 

 

 

 

Immunology in the liver: from homeostasis to disease

Felix Heymann,

Aachen university, Germany

 

 

 

 

 

 

 

Liver cirrhosis as a prothrombotic condition

Mark Thursz

Imperial College, London, UK

 

 

 

 

 

 

 

Endoscopy in patients with liver disease: selected topics and NLI experience

Hossam Taha & Hassan Zaghla

National Liver Institute, Egypt

 

 

 

 

 

The clinical scenario of drug-induced liver injury

Piero Almasio

University of Palermo, Italy

 

 

 

 

 

 

Case reports at the National Liver Institute

Omkolsoum Elhaddad

National Liver Institute, Egypt

 

 

 

 

 

 

What after viral cure: health and liver optimization

Christophe Hézode

Paris XII University, Créteil, France

 

 

 

 

 

Real life experience of HCV treatment at the National Liver Institute

Eman Rewisha

National Liver Institute, Egypt

 

 

 

 

 

DAAs in decompensated cirrhosis

Piero Almasio

University of Palermo, Italy

 

 

 

 

 

 

HCV in the era of liver transplantation

Christophe Hézode

Paris XII University, Créteil, France

 

 

 

 

 

 

Implications of gut microbiota in NAFLD

Mark Thursz

Imperial College, London, UK

 

 

 

 

 

 

 

NASH beyond the acronym: certainties and clinical dilemmas

Piero Almasio

University of Palermo, Italy

 

 

 

 

 

 

 

New perspectives in the diagnosis of NAFLD

Tary Salman

National Liver Institute, Egypt

 

 

 

 

 

Novel therapeutics for NAFLD

Mohsen Salama

National Liver Institute, Egypt

 

© National Liver Institute 2016